Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - ObsEva (Details)

v3.23.2
Licensing and Other Arrangements - ObsEva (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Nov. 21, 2022
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Asset acquisition            
Changes in estimated fair value of contingent consideration       $ 75    
Estimated useful life of intangible asset 17 years          
Amortization expense   $ 224   449    
Revenue recognized   1,125 $ 525 1,125 $ 3,275  
License Agreement | ObsEva            
Asset acquisition            
Contract assets   0   0   $ 0
Contract liabilities   0   0   0
Revenue recognized   0   0    
License Agreement | ObsEva, Organon            
Asset acquisition            
Maximum eligible milestone payments receivable upon achievement of development, commercialization and sales-based milestones $ 475,000          
License Agreement | ObsEva, Merck KGaA            
Asset acquisition            
Maximum earn-out payments for development and regulatory milestones 46,500          
Maximum earn-out payments for sales-based milestones 51,000          
ObsEva IP            
Asset acquisition            
Upfront cash payment to acquire assets 15,000          
Cost to acquire assets 15,200          
Transaction costs $ 200          
Estimated useful life of intangible asset 17 years          
Impairment of intangible asset       0   $ 0
Amortization expense   $ 200   $ 400    
ObsEva IP | License Agreement            
Asset acquisition            
Maximum earn-out payments $ 97,500